menu
    • menu
    [{"orgOrder":0,"company":"Epic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Not Applicable"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Not Applicable"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Solve FSHD","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"EPI-321","moa":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Solve FSHD","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Solve FSHD"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CAR T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Kite Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Epic Bio \/ Kite Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Epic Bio

    Menu

    Epic Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Kite Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

                            Details : Under the agreement, Kite will gain access to Epic Bio’s gene regulation platform to potentially develop next-generation cancer cell therapies and Epic Bio will develop constructs for Kite-selected targets for use in CAR T-cell therapies directed to bl...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Kite Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Solve FSHD

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            SOLVE FSHD Invests in Epic Bio for The Development of A Novel Treatment for Facioscapulohumeral Muscular Dystr...

                            Details : The investment will support development of Epic’s lead program EPI-321, a novel therapeutic that is designed to correct the epigenetic alterations in the D4Z4 region of chromosome 4.

                            Brand Name : EPI-321

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 18, 2023

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Solve FSHD

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Epic Bio Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery

                            Details : EPI-321 is being studied for the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is caused by a loss of methylation of the D4Z4 region, leading to an abnormal expression of the DUX4 gene on chromosome 4, normally only expressed during em...

                            Brand Name : EPI-321

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 31, 2022

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Epic Bio

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Epic Bio Presents Proprietary Gene Expression Modulation System (GEMS) Demonstrating Precise Engineering of DU...

                            Details : EP1-321, platform integrates its dCas proteins with customized guide RNA, in studiy of results from invitro it demonstrate the utility of our dCas to suppress DUX4 expression by up to 95%.

                            Brand Name : EPI-321

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 13, 2022

                            Lead Product(s) : EPI-321

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth